Flagship VentureLabs IV LLC 13D and 13G filings for Seres Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2022-07-07 5:00 pm Purchase | 2022-07-05 | 13D | Seres Therapeutics, Inc. MCRB | Flagship VentureLabs IV LLC | 23,493,063 18.900% | 8,443,072 (+56.10%) | Filing |
2020-11-25 4:30 pm Sale | 2020-11-23 | 13D | Seres Therapeutics, Inc. MCRB | Flagship VentureLabs IV LLC | 15,049,991 16.500% | -6,596,914 (-30.48%) | Filing |